UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

Kielhorn, A; Porter, Duncan; Διαμαντόπουλος, Α.; Lewis, Gavin

doi:10.1185/03007990802321683

Cited by 49 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kielhorn et al 144 considered two different RTX pathways (RTX followed by traditional DMARDs compared with traditional DMARDs only and RTX first, then switch to ADA if there was no response, then switch to IFX if there was no response, then switch to traditional DMARDs, compared with ADA first, then switch to IFX, then switch to conventional DMARDs). Lindgren et al 145 considered RTX first, followed by a series of TNF inhibitors compared with a series of TNF inhibitors.…”

Section: Resultsmentioning

confidence: 99%

“…Russell et al 144 also extracted the effectiveness of TNF inhibitors in patients with an inadequate response to TNF inhibitors from the ATTAIN trial, [127][128][129][130][131][132] assuming a 10% reduction after each switch. The same study also used the TEMPO (Trial of Etanercept and Methotrexate with radiographic Patient Outcomes) trial as the source for ETN effectiveness, when ETN appears in the sequence for the first time in patients with an inadequate response to DMARDs.…”

Section: Data Sourcementioning

confidence: 99%

See 1 more Smart Citation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAAdalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Dr Paresh Jobanputra has participated in several technology assessments/appraisals related to rheumatoid arthritis as the clinical expert of the assessment group. He works as consultant rheumatologist in a large department of rheumatology. His department has taken part in clinical trials of etanercept, adalimumab, rituximab and tocilizumab. The department receives funding for nurses from Schering-Plough Ltd to administer infliximab to patients currently being treated with this drug. Currently he is the chief investigator of a clinical trial comparing adalimumab versus etanercept (ISRCTN95861172). He has, in the past, received support for educational purposes from Wyeth Pharmaceuticals (etanercept), Abbott (adalimumab) and Roche (rituximab). He has also been involved in an advisory board for Roche in relation to tocilizumab and rituximab, and has accept...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Data Sourcementioning

confidence: 99%

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

show abstract

“…Kielhorn et al (2008) found that rituximab after two TNF failures was cost-effective. [56] None of the studies considered the optimal position of rituximab, comparing rituximab after one or two TNF failures.…”

Section: Health Economic Results In Established Ramentioning

confidence: 99%

Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review

2014

View full text Add to dashboard Cite

The objective was to assess and critique how sequential disease modifying therapies (DMARDs) have been modelled in the context of economic evaluations of the use of DMARDs for the treatment of Rheumatoid Arthritis (RA). A secondary aim was to identify the methodological challenges of modelling sequential therapies.Systematic searches of 10 databases were undertaken in February 2013. Studies were included if they were English language and reported a full comparative economic evaluation, and they were appraised using the Drummond checklist. Data extracted included economic evaluation data, data relating to sequential treatments, and data on the modelling methods used. 57 studies were identified, with 25 (44%) modelling a sequence of treatments. 43 (75%) were cost-utility analyses. 11 (19%) were UK, and 11 (19%) were US. The remainder were mainly European (26 (46%) studies).There was a distinction between studies in recent-onset RA (14 (25%)), and those in established RA (42 (74%)).One study (1%) was unclear. Individual level models were more likely to meet the Drummond criteria and evaluate sequences. No study identified an optimal sequence of multiple treatments given a set of alternative treatments. The level of reporting about the methods and evidence used to assess the impact of future treatments was generally poor. Where models considered a lifelong time horizon and downstream treatment sequences, evidence gaps were identified.The review identified that methods have not been consistently applied, leading to varied estimates of costeffectiveness. Treatment sequences have not been fully considered and modelled, potentially producing inaccurate estimates of cost-effectiveness.

show abstract

“…The Abatacept (ABA) has recently been investigated, this results suggested that is costeffective for moderate to severe RA after failure to MTX; based on data from the AIM study (38), resulting in $ 47,910 per QALY gained over 10 years and $ 43,041 to ITH. When failures after one or more anti-TNF are analyzed, Rituximab (RTX) has been profitable (39), this based on data modeling of the REFLEX study. The RTX resulted in QALY gained of 0.526 years.…”

Section: Economic Evaluations Of the Rheumatic Diseasesmentioning

confidence: 99%

Economic Impact of Rheumatic Diseases

Quintana¹,

Coral-Alvarado²

2011

Challenges in Rheumatology

View full text Add to dashboard Cite

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

Cited by 49 publications

References 30 publications

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review

Economic Impact of Rheumatic Diseases

Contact Info

Product

Resources

About